FDA Approves First DNA Test for Opioid Use Disorder

On Dec. 19, the FDA approved AvertD, the first DNA test to identify elevated risk of opioid use disorder (OUD) in individuals before they are prescribed opioid pain medications following surgery.

The test is available by prescription only and is intended for acute pain patients, and AutoGenomic Inc. must train providers on its use and conduct a post-market study.